https://news.abbvie.com/2023-11-30-AbbVie-to-Acquire-ImmunoGen,-including-its-Flagship-Cancer-Therapy-ELAHERE-R-mirvetuximab-soravtansine-gynx-,-Expanding-Solid-Tumor-Portfolio AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio Proposed acquisition will accelerate AbbVie's entry into the commercial market for ovarian cancer ELAHERE is a first-in-class antibody-drug conjugate (ADC) approved for platinum-resi...
#
AbbVie
#
ADC
#
IMGN
#
ImmunoGen
#
애브비
원문 링크 : 애브비, 이뮤노젠(IMGN) 인수
